Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Market

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Apr 04, 2022 4:43pm

198 Views

Post# 34574535

RE:Market

It simple really.. they gave up on the IR front and are solely relying on results to drive the share price. They tell themselves been there done that in the last 30 years and we already crashed and burned the analysts, the market, etc... let it be and hope for the best. If you buy this stock you have to believe POC in Th1902 will drive value.. otherwise it's a 2$ stock.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property